Altimmune Inc (ALT) last year’s performance of 202.16% is a clear signal for an entertaining trading season.

SQ

On Monday, Altimmune Inc (NASDAQ: ALT) opened higher 4.78% from the last session, before settling in for the closing price of $6.69. Price fluctuations for ALT have ranged from $2.24 to $14.84 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 115.21%. Company’s average yearly earnings per share was noted 16.61% at the time writing. With a float of $70.48 million, this company’s outstanding shares have now reached $70.68 million.

Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is -4899.02%, operating margin of -23785.57%, and the pretax margin is -24778.97%.

Altimmune Inc (ALT) Breakdown of a Key Holders of the stock

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Altimmune Inc is 0.83%, while institutional ownership is 59.61%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.

Altimmune Inc (ALT) Recent Fiscal highlights

If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.39 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.42) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 16.61% per share during the next fiscal year.

Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators

Check out the current performance indicators for Altimmune Inc (ALT). In the past quarter, the stock posted a quick ratio of 11.30. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1215.12.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.52 in one year’s time.

Technical Analysis of Altimmune Inc (ALT)

Looking closely at Altimmune Inc (NASDAQ: ALT), its last 5-days average volume was 1.41 million, which is a drop from its year-to-date volume of 3.81 million. As of the previous 9 days, the stock’s Stochastic %D was 53.07%. Additionally, its Average True Range was 0.41.

During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 53.97%, which indicates a significant decrease from 82.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.03% in the past 14 days, which was lower than the 78.21% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $6.78, while its 200-day Moving Average is $7.80. However, in the short run, Altimmune Inc’s stock first resistance to watch stands at $7.21. Second resistance stands at $7.41. The third major resistance level sits at $7.63. If the price goes on to break the first support level at $6.79, it is likely to go to the next support level at $6.57. Now, if the price goes above the second support level, the third support stands at $6.37.

Altimmune Inc (NASDAQ: ALT) Key Stats

There are currently 70,902K shares outstanding in the company with a market cap of 498.20 million. Presently, the company’s annual sales total 430 K according to its annual income of -88,450 K. Last quarter, the company’s sales amounted to 10 K and its income totaled -24,640 K.